N-Acetyle-Cysteine in the treatment of obsessive-compulsive disorder

N-Acetyle-Cysteine as adjuvant therapy in moderate to severe OCD : a double blind randomised clinical trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201405271556N60

Enrollment

Registered

2014-05-27

Start date

2014-06-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obsessive- Cumpulsive Disorder. Obsessive-compulsive disorder

Interventions

Intervention 1: fluvoxamine 100 mg/day+ N-Acetyl cysteine 200 mg/day for 10 weeks as intervention group. Intervention 2: Fluvoxamine 100 mg/day + placebo for 10 weeks as control group.

Treatment - Drugs

Placebo

fluvoxamine 100 mg/day+ N-Acetyl cysteine 200 mg/day for 10 weeks as intervention group

Fluvoxamine 100 mg/day + placebo for 10 weeks as control group

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: 1-Age between 18-60, 2-Diagnosis of OCD based on DSM V 3 , Minimum Score of 21 on YALE-BROWN Obsessive-Compulsive Scale- Exclusion Criteria:1- Substance dependence,2- IQ <70,3-any other mental disorder on axis I, 4-Any serious cardiac, renal or hepatic disease ,5- receiving psychotropic medications during the last 6 weeks 6- pregnancy or breast feeding 7-rising liver transaminases to three times the upper limit of normal or higher

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Severity of symptoms of OCD. Timepoint: Baseline and weeks 2-4-8-10 after beginig of treatment. Method of measurement: Y_BOCS.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactProf. Shahin Akhondzadeh

Tehran University of Medical Sciences

s.akhond@sina.tums.ac.ir+98 21 5541 2222

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Mar 2, 2026